Investors Take Note: Faruqi & Faruqi Seeks to Help
Faruqi & Faruqi, LLP, a prominent national securities litigation firm, is leading an investigation focusing on investors who may have sustained significant losses with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The firm encourages those who believe they have suffered losses of over $100,000 due to the company’s practices to reach out directly for legal support and consultations.
Understanding Potential Claims Against Regeneron
The firm is aware of allegations against Regeneron that could have serious implications for its investors. The claims outline a worrying picture of potential violations of federal securities laws, which includes making misleading statements regarding drug pricing and sales practices.
What the Allegations Involve
One of the core issues at hand is that Regeneron allegedly paid credit card fees to distributors, under the condition that these distributors would not charge more to consumers using credit cards during purchases of their drug, Eylea. This practice reportedly led to a price concession that misrepresented sales figures and impacted the overall pricing strategy.
Impact of Regulatory Actions
In a significant development, the U.S. Department of Justice has filed a complaint against Regeneron under the False Claims Act. This complaint claims that the company failed to report discounts provided to drug distributors, thereby inflating the Average Selling Price (ASP) of Eylea, leading to unauthorized increases in Medicare reimbursements. This controversy indicates a troubling trend in compliance and ethical business practices.
Market Reactions and Stock Movements
The consequences of the company’s actions have been felt acutely in its stock performance. Following the DOJ’s disclosure, Regeneron experienced a notable stock price drop, sinking by $31.50, or 3.36%, within two trading days. This decline can be attributed to diminished investor confidence stemming from the ongoing legal scrutiny.
Investor Concerns and the Latest Financial Reports
On October 31, 2024, Regeneron released its third-quarter earnings, which were significantly below market expectations, further contributing to a $84.59 drop in share price. The results indicated that sales for Eylea HD were disappointing, exacerbating concerns among analysts and investors regarding the company’s future performance.
Participation in the Upcoming Class Action
As the investigation progresses, the role of a lead plaintiff becomes critical. This individual is responsible for representing the interests of all class members in litigation efforts. If you believe you could play this role or wish to remain an anonymous class member, it’s crucial to stay informed and aware of your legal options as this situation develops.
How to Get Involved
Investors who have been impacted by these developments are encouraged to communicate with Faruqi & Faruqi. Whether you have pertinent information, are a whistleblower, a former employee, or a shareholder, sharing your insights could prove beneficial not only to your case but also to the larger investor community.
Contact Information and Further Details
For inquiries related to your specific circumstances or the overarching class action concerning Regeneron Pharmaceuticals, you can reach out to Josh Wilson, a partner at Faruqi & Faruqi, directly at the provided contact numbers. Additionally, keep an eye on updates via their official channels for ongoing developments regarding this significant case.
Frequently Asked Questions
What is the purpose of the investigation by Faruqi & Faruqi?
The investigation aims to explore potential securities law violations by Regeneron Pharmaceuticals, which may have caused financial losses to their investors.
Who can participate in the class action against Regeneron?
Anyone who has suffered losses exceeding $100,000 in Regeneron between the specified dates is eligible to participate in the class action.
What are the financial implications of the DOJ's complaint against Regeneron?
The complaint suggests that Regeneron's financial reporting may have been misleading, potentially leading to inflated revenue figures and consequently impacting its stock price.
How do I contact Faruqi & Faruqi for assistance?
You can contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for guidance regarding the claims.
What should I do if I have information regarding Regeneron's practices?
If you have information related to Regeneron’s conduct, it’s important to reach out to Faruqi & Faruqi to share your insights and aid the investigation.
